Dacarbazine (DTIC-Dome) is an antineoplastic agent. It has significant activity against melanomas.

Dacarbazine 通过Fas非依赖途径介导的可以使黑色素瘤对特定肽CTL的溶解更为敏感[2]。

Axitinib和Dacarbazine 联合治疗在对抗黑色素瘤侧方异种移植物方面展现了显著的抗肿瘤活性，能减少肿瘤细胞增殖，减小肿瘤坏死面积，并促进细胞凋亡。此外，Dacarbazine可降低与转移相关的因子，并延长小鼠的生命期[3]。

Apotosis assay: UACC903 (UACC) cells treated with or without DTIC (20 μM) for 48 h are incubated with agonist anti-Fas Ab, CH-11 (500 ng/ml), for 5 and 16 h, respectively. To distinguish whether death/apoptosis is mediated by FasR, blocking anti-Fas Ab ZB4 (2 mg/ml) is added in the corresponding groups. At the end of incubation, cells are harvested and stained with propidium iodide and FITC-annexin V (BD PharMingen) for detecting apoptosis according to the instruction provided by the company. Ten thousand cells from each group are collected, and dead and apoptotic cells are analyzed without gating using CellQuest software. (Only for Reference)